Abstract: We present ah ollow-structured rigid nanovesicle (RNV) fabricated by am ulti-stage microfluidic chip in one step,t oe ffectively entrap various hydrophilic reagents inside, without complicated synthesis,extensive use of emulsifiers and stabilizers,a nd laborious purification procedures.T he RNV contains ah olloww ater core,arigid poly (lactic-co-glycolic acid) (PLGA) shell, and an outermost lipid layer.T he formation mechanism of the RNV is investigated by dissipative particle dynamics (DPD) simulations.T he entrapment efficiency of hydrophilic reagents such as calcein, rhodamine B and siRNAinside the hollowwater core of RNV is % 90 %. In comparison with the combination of free Dox and siRNA, RNV that co-encapsulate siRNAa nd doxorubicin (Dox) reveals as ignificantly enhanced anti-tumor effect for am ultidrug resistant tumor model.
Rigid nanoparticles are effective for delivery of therapeutic agents.W eh ave shown that rigid PLGA-lipid nanoparticles (PLGA = poly (lactic-co-glycolic acid)) loaded with hydrophobic drugs display an enhanced cellular uptake and cancer treatment compared to flexible PLGA-lipid nanoparticles of similar properties. [1] In addition to hydrophobic therapeutic agents,h ydrophilic reagents,s uch as small interfering RNA (siRNA), plasmids,protein, some anticancer drugs,and some small molecular fluorescent probes,h old great promise in molecular biology and pharmaceutical sciences.Compared to hydrophobic drugs,n anocarriers for hydrophilic chemicals are generally required because:1)some hydrophilic reagents such as nucleic acids are reluctant to be uptaken by cells and unstable without encapsulation; [2] 2) some hydrophilic therapeutic agents show rapid metabolism and thus very short circulation half-life. [3] Despite of an explosive development of nanocarriers including liposomes, [4] block copolymers, [5] and hybrid nanoparticles [6] for hydrophobic drugs delivery,several issues arise in adopting nanocarriers for encapsulation of hydrophilic reagents (e.g.,t he relatively low entrapment efficiency of drugs, [7] low drug recovery rate, [8] limited applications of charge-based delivery systems, [9] and difficulty in synthesis of nanocarriers [8b, 10] ). To address the above challenges,aversatile,s table,a nd easy-to-fabricate nanocarrier for delivering hydrophilic chemicals is in high demand. [11] Hybrid core-shell nanoparticles are becoming anew class of drug nanocarriers,w hich comprise ap olymeric core,f or example,PLGA, to carry hydrophobic drugs and reagents, [12] and an outer lipid shell to prolong the circulation half-life. [13] In contrast to bulk approaches usually involving complicated procedures and limited experimental control, [12a,14] microfluidicp latforms have been employed for controlled generation of hybrid nanoparticles in ar apid and straightforward manner. [15] However,anefficient encapsulation of hydrophilic drugs will necessitate ah ollow structure.T os ynthesize the hollow core-shell nanoparticles,t he formation of reverse micelles is always involved, which can only be stable for avery short time without the protection from emulsifiers and stabilizers.I nb ulk fabrication of reverse micelles by the double emulsion method, [14c] the extensive use of emulsifiers and stabilizers may lead to the increased toxicity,a nd the following purification process is complicated. Them icrofluidic approach may facilitate the generation of hollow coreshell nanoparticles due to the precise fluids control and rapid mixing in small scales, [16] but has not been realized yet. Here we report on am ulti-stage microfluidic chip to manufacture water core/PLGA shell/lipid layer rigid nanovesicles (RNVs) to entrap varying hydrophilic reagents into the water core regardless of their properties such as molecular weight, surface charge,a nd so forth. We refer to this nanocarrier as rigid nanovesicle because compared to lipid/ cell membrane-like vesicles with Youngs modulus of % 1MPa, the PLGA shell in RNV results in am uch stiffer structure with Youngs modulus of % 1GPa.
[4a] Them icrofluidic chip consists of three stages:1)The first stage has three inlets and as traight channel (two side inlets for introducing PLGA and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) in N,N-dimethylformamide (DMF), and one center inlet for hydrophilic reagents such as siRNA, calcein and rhodamine Binwater). 2) Thesecond stage has two side inlets for water sheaths and one straight channel. 3) Thethird stage has one center inlet for DPPC,D SPE-PEG,a nd cholesterol in ethanol and as piral channel (Scheme 1a nd Figure S1 in the Supporting Information). In this work, the flow rate ratio (FR) of side inlets to middle inlet at different stages is optimized for synthesis of RNV,and the production rate of RNV is 114 mgmin À1 by the microfluidic chip (Supporting Information). Thetransmission electron microscopy (TEM) image of an assembled RNV collected from the outlet shows ahollow core-shell structure with abright water core and an intact PLGA shell ( Figure 1A ). We use the positively charged DOTAP to form the reverse micelle as well as the inner surface of PLGA shell because DOTAPc an interact with the negatively charged siRNA, thus ensuring an efficient encapsulation of siRNAi nside the water core. Meanwhile,t he lipids (DPPC,D SPE-PEG,a nd cholesterol) are assembled onto the outer surface of PLGA shell in the third stage of microfluidic chip,i no rder to achieve al ongterm stabilization and al ong circulation time.
We first encapsulate hydrophilic reagents,such as calcein, rhodamine Ba nd siRNA, into the water core of RNV by microfluidic chips,and characterize the entrapment efficiency and the size of RNV.T he entrapment of calcein (or rhodamine B) into the RNV and the entrapment efficiency are investigated using the spectrofluorophotometer and the microplate reader (Figure 1B, C and Figures S2 and S3) . To validate the encapsulation of siRNAi nto the RNV and quantify the entrapment efficiencyo fs iRNA, we compare the gel retardation assays of free siRNA, lysed RNV loaded with siRNA( RNV is lysed by three cycles of freeze-thaw and sonication), and untreated RNV loaded with siRNA( RNV-[siRNA],S upporting Information). Thea mount of siRNAr eleased from the lysed RNV[siRNA] (the middle band) is almost the same as that of free siRNAc ontrol (the left band), while free siRNA signal (the right band) in the untreated RNV-
[siRNA] solution is barely observed, indicating the high siRNArecovery rate ( % 98 %) and loading efficiency in RNV ( Figure 1D ).
Them easured hydrodynamic diameter of the RNV encapsulating different hydrophilic reagents is around 140 nm, and the polydispersity index (PDI) is smaller than 0.25 by dynamic light scattering (DLS) ( Table 1) . RNV loaded with different hydrophilic reagents shows marginal differences in size and PDI. Thesurface charges of the RNV encapsulating different reagents can be influenced by the contents.Briefly,the positively charged DOTAP may diffuse to the outer lipid layer, resulting in the positive surface charge of RNV when encapsulating calcein and rhodamine B. However,f or fabrication of RNV encapsulating siRNA, the negatively charged siRNAw ill interact with the DOTAP, thus limiting the diffusion of DOTAP and resulting in the negative surface charge of RNV (Supporting Information). Theentrapment efficiencies of three hydrophilic reagents into the RNV are almost 90 % ( Table 1) , approximately 1.5 times Angewandte Chemie higher than bulk methods. [17] To investigate the degradation kinetics,wemonitor the release curve of Dox encapsulated by the PLGA shell of RNV,w hich directly indicates the degradation of PLGA shell. Thed egradation of PLGA shell would ultimately result in the release of siRNAi nside the water core of RNV ( Figure S5 ). Forthe degradation of RNV, the PLGA shell plays ak ey role which forms ab arrier to protect siRNAand holds the whole structure,while the lipids can further sustain the degradation as ar esult of the PEG chain.
[8b]
To investigate the intermediates involved in the formation process of RNV within the microfluidic channel that are difficult to capture and characterize experimentally,w e carried out dissipative particle dynamics (DPD) simulations, at ool to study dynamical behavior of vesicles and polymers on the molecular scale.I nt he first stage,w ef ind that water can form droplets quickly under the interfacial tension between water and lipids will assemble onto the surface of the water droplets to form reverse micelles in the cuboid simulation box (Figure 2A ,s ee Supporting Information for simulation details). In the second stage,w ep ut the asfabricated system into the center of al arger cuboid box, and add water beads into it. Similarly,under the interfacial tension between PLGA and water, the PLGA will shrink and form RNV ( Figure 2B ). At the same time,several reverse micelles inside PLGA shell can fuse to one bigger micelle,and excess lipids would diffuse to the surface of PLGA shell ( Figure 2C ). In the third stage,m ore lipids added into the system will assemble onto the outer surface of PLGA shell via interaction between PLGA and the hydrophobic tail of lipids.
We used am ulti-drug resistant cancer model to evaluate the biological efficacy of hydrophilic chemicals delivered by RNV.Inthis model, the cells express high level of multi-drug resistant (MDR1) protein, which pumps out the anticancer drugs such as doxorubicin (Dox). To knock down MDR1, siMDR1 (the siRNAsequence against the MDR1 mRNA) is utilized in combination with Dox. [14b,18] With am ulti-stage microfluidic chip,w ef abricate ac o-delivery RNV with siRNAi nt he water core and Dox in the PLGA shell. The entrapment efficiencyo fD ox is 96.6 AE 1.1 %, and that of siRNAi s9 1.23 AE 4.51 %( Table 1 , and Supporting Information). Thep resence of the lipids (DPPC,D SPE-PEG,a nd cholesterol) as the outermost layer and the high rigidity of RNV may lead to an enhanced cellular uptake. [1] Thecellular uptake of RNV is experimentally tested by co-incubation of RNV loaded with siMDR1 and Dox (RNV[Dox/siMDR1]) and MCF-7/ADR cells for 2hin medium supplemented with 10 %f etal bovine serum (FBS). Them easured fluorescence signals from Dox indicate that almost 100 %ofMCF-7/ADR cells can uptake RNV[Dox/siRNA],while free Dox can only diffuse into 30 %o fc ells ( Figure 3A ,B,S upporting Information). Theability to carry out the transfection in the presence of serum is ac lear advantage for RNV.
We next evaluate the gene knockdown efficiency by RNV[Dox/siRNA] using the real-time quantitative polymerase chain reaction (RT-qPCR). RNV[Dox/siMDR1] achieves an enhanced gene knockdown efficiency of ca. 80 %, much better than that of the same amount of siMDR1 and Dox delivered by lipofectamine 2000 ( Figure 3C ). In comparison, the blank vesicles plus Dox, and RNV loaded with negative control siRNAa nd Dox (RNV[Dox/siNC]) display . .
no knock-down effects of MDR1 mRNA. We also investigate the cell apoptosis induced by RNV ( Figure S7 Figure 4A -C and Supporting Information). To evaluate the safety of RNV,w em easure hemolysis and weight change of mice.The measurement of hemoglobin leaked from red blood cells incubated with RNV [Dox/ siMDR1] shows that RNV cannot induce hemolysis (Figure S8) . Thew eight of the mice before and after the treatments kept essentially constant, indicating al ow level of toxicity of RNV ( Figure 4D) .
In this work, we develop at hree-stage microfluidic platform that can assemble water core/PLGA shell/lipid layer RNV in one step for delivering varying hydrophilic reagents without having to use emulsifiers and stabilizers.For am ulti-drug resistant tumor model, an enhanced anti-tumor effect is observed by co-delivering siMDR1 and Dox using RNV in both in vitro and in vivo experiments.R NV also proves to be asafe and biocompatible nanocarrier for in vivo treatment. With these attractive properties,w eb elieve that RNV would be apromising carrier for high efficient delivery of hydrophilic theranostic agents,r anging from cancer treatment to in vivo imaging diagnosis.
Keywords: drug delivery ·hydrophilic reagents ·microfluidics · nanoparticles ·vesicles Figure 4 . In vivo anti-tumor effects on am ulti-drug resistant tumor model. A) Measurement of relative tumor volume growth after treatment. The day before the first dose is specified as day 0. The black arrow on the axis shows the day of administration. B) Weight of the excised tumors. C) Photo of the excised tumors. Scale bar,1cm. D) Body weight of the mice before and after the administration. *P < 0.05, **P < 0.01, siNC:negative control siRNA.
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